Role of osteopontin in tumour progression - PubMed (original) (raw)

Review

Role of osteopontin in tumour progression

S R Rittling et al. Br J Cancer. 2004.

Abstract

Since its first identification as a transformation-associated protein, osteopontin (OPN) has been recognised as important in the processes of tumorigenicity and metastasis. Here, we review the evidence that OPN might be considered as a candidate prognostic marker in human cancer. In animal systems, evidence from cell injection experiments and genetically manipulated mice suggest an important but complex role for the protein in tumour progression. Moreover, studies in a variety of human cancers associate high levels of OPN expression in tumours or in blood with more advanced cancers. The mechanism of action of OPN in promoting cancer is still unclear, and we consider aspects of OPN biology that can complicate interpretation of human studies. Nevertheless, growing evidence supports a role for OPN as a potential prognostic factor for various human cancers.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ (2002) Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 94: 513–521 - PubMed
    1. Ariztia EV, Subbarao V, Solt DB, Rademaker AW, Iyer AP, Oltvai ZN (2003) Osteopontin contributes to hepatocyte growth factor-induced tumor growth and metastasis formation. Exp Cell Res 288: 257–267 - PubMed
    1. Barraclough R, Chen HJ, Davies BR, Davies MP, Ke Y, Lloyd BH, Oates A, Rudland PS (1998) Use of DNA transfer in the induction of metastasis in experimental mammary systems. Biochem Soc Symp 63: 273–294 - PubMed
    1. Bautista DS, Saad Z, Chambers AF, Tonkin KS, O'Malley F, Singhal H, Tokmakejian S, Bramwell V, Harris JF (1996) Quantification of osteopontin in human plasma with ELISA: basal levels in pre- and postmenopausal women. Clin Biochem 29: 231–239 - PubMed
    1. Behrend EI, Craig AM, Wilson SM, Denhardt DT, Chambers AF (1994) Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res 54: 832–837 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources